AbbVie EBITDA 2010-2024 | ABBV

AbbVie EBITDA for the quarter ending September 30, 2024 was $5.910B, a 30.87% increase year-over-year.

  • AbbVie 2023 EBITDA was 21.455B, a 19.29% decline from 2022.
  • AbbVie 2022 EBITDA was 26.584B, a 0.53% increase from 2021.
  • AbbVie 2021 EBITDA was 26.445B, a 48.28% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

AbbVie EBITDA 2010-2024 | ABBV

  • AbbVie 2023 EBITDA was 21.455B, a 19.29% decline from 2022.
  • AbbVie 2022 EBITDA was 26.584B, a 0.53% increase from 2021.
  • AbbVie 2021 EBITDA was 26.445B, a 48.28% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$692.7B
Novo Nordisk (NVO)$460.6B
Johnson & Johnson (JNJ)$368.4B
Merck (MRK)$244.2B
Novartis AG (NVS)$211.1B
AstraZeneca (AZN)$197.8B
Pfizer (PFE)$142.2B
Sanofi (SNY)$121.8B
Innoviva (INVA)$1.2B